Clifford Chance

Clifford Chance advises DSM and Sinochem on disposal of DSM Sinochem Pharmaceuticals to Bain Capital

Clifford Chance has advised Royal DSM (“DSM”), a global science-based company in Nutrition, Health and Sustainable Living, and Sinochem Group (“Sinochem”), a Fortune 500 enterprise on the disposal of their 50/50 joint venture DSM Sinochem Pharmaceuticals (“DSP”), the global leader in sustainable antibiotics, next-generation statins and anti-fungals to Bain Capital Private Equity, a leading global private investment firm. The transaction is expected to be completed in the fourth quarter of 2018, subject to customary regulatory approvals and consultations.

DSP is headquartered in Singapore, develops, produces and sells intermediates, active pharmaceutical ingredients and finished dosage form pharmaceuticals. In 2017, the company generated sales of approximately EUR 440 million. It has manufacturing sites and sales offices in China, India, the Netherlands, Spain, the USA and Mexico, with approximately 2,000 employees.

The Clifford Chance team that advised DSM and Sinochem was led by Greg Crookes and Line Poliquin and included Liesbeth Buiter, Laura Franklin, Evert van der Kaa, Pieter Leefers, Rona Nisar, Willemijn de Wit, Amir Adl Rudbordeh, Carlijn Tenge, Sophie van Marwijk Kooy (Corporate), Michiel Sunderman, Daan Smole (Tax), Serkan Özel (notary), Floris van de Bult, Sara Schermerhorn, Bart Bootsma (Employment), Juliette Luycks, Sanne Blankestijn (L&DR), Alvin Khodabaks, Jaap Tempelman, Andrei Mikes (IT/IP), Angela McEwan, Megan Roberts, Rick Verhagen (FMG), Frans Muller, Celine Vermeulen, Jurre Jurriëns (Antitrust). Other offices that were involved: Roger Leese, Nick Mace, Jan Hobbs (London), Brice Hillen (Brussels), Kimi Liu, Jane Chen (Bejing), María Begoña Barrantes, Jorge Martín-Fernández, Diego Doménech, (Madrid), Charmaine Yeo (Singapore), Jay Liang, Echo Yang (Shanghai), Emma Davies, Thomas Walsh, Angel Yao and Dianna Shao (Hong Kong).